24/7 Wall Street
14 Apr 2026, 17:56 UTC · 30w ago
Impact · against what's priced in
JNJ and JPM show strong operational resilience and dividend safety, though JNJ's Stelara decline is a known headwind. ADX remains a viable equity-risk vehicle, but its yield variability is a structural characteristic rather than a catalyst.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Johnson & Johnson raised its quarterly dividend by 3.1% to $1.34 per share and increased its full-year 2026 adjusted EPS guidance to $11.45–$11.65.
More positive than 77% of claims this week
JPMorgan Chase reported Q1 2026 net income of $16.49 billion, up 13% year-over-year, with a CET1 ratio of 14.3%.
Continue reading
5 related stories
Q1 2026 net income grew 13% year-over-year to $16.49 billion, supported by a strong CET1 ratio of 14.3%.
Read from the article alone
No priced-in read yet
Management raised full-year 2026 adjusted EPS guidance to $11.45–$11.65 and increased the dividend by 3.1%, despite a 59.7% revenue drop for Stelara.
Read from the article alone
No priced-in read yet
The fund trades at a 3.2% discount to NAV and maintains a minimum 8% distribution target, though total payouts vary based on realized capital gains.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 64% of claims this week
JNJ's Stelara biosimilar headwind caused a 59.7% revenue drop for that specific drug to $656 million in Q1.
More negative than 68% of claims this week
The Adams Diversified Equity Fund (ADX) targets a minimum annual distribution rate of 8% of NAV, but the year-end special distribution is variable and dependent on realized capital gains.
More positive than 43% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Reports strong net income growth, a very strong balance sheet, and a well-covered, growing dividend.
More positive than 88% of ticker scores this week
Strong dividend growth streak, raised full-year guidance, and growth in the Innovative Medicine segment despite biosimilar headwinds.
More positive than 78% of ticker scores this week
The fund has a strong total return record, shares are trading at a discount to NAV, and quarterly distributions are described as safe.
More positive than 48% of ticker scores this week
Mentioned as a large holding that recently raised its dividend in late 2025.
Near neutral — 90% of ticker scores this week are stronger
Mentioned as a large holding contributing to capital appreciation but providing modest dividends.
Near neutral — 90% of ticker scores this week are stronger
Listed as a top holding in the fund's portfolio without specific performance commentary.
Near neutral — 90% of ticker scores this week are stronger
Mentioned as a large holding contributing to capital appreciation but providing negligible dividends.
Near neutral — 90% of ticker scores this week are stronger
Listed as a top holding in the fund's portfolio without specific performance commentary.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
27m ago
More positive than 75% of relationship scores this week
[a_to_b] ADX holds JPMorgan Chase as a position in its portfolio.
More positive than 75% of relationship scores this week
[a_to_b] ADX holds Apple as one of its five largest equity positions.
More positive than 75% of relationship scores this week
[a_to_b] ADX holds Amazon as one of its five largest equity positions.
More positive than 75% of relationship scores this week
[a_to_b] ADX holds Microsoft as one of its five largest equity positions.
More positive than 75% of relationship scores this week
[a_to_b] ADX holds NVIDIA as one of its five largest equity positions.
More positive than 75% of relationship scores this week
[a_to_b] ADX holds Alphabet as one of its five largest equity positions.
+9.7%
Price agrees with the score
$344.26 vs $313.68 close before publication (Apr 13) · not market-adjusted
JPM chart →+20.1%
Price agrees with the score
$285.74 vs $237.96 close before publication (Apr 13) · not market-adjusted
JNJ chart →+5.4%
Price agrees with the score
$24.94 vs $23.66 close before publication (Apr 13) · not market-adjusted
ADX chart →
